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Abstract
Background
Macrophages play a crucial role in the interaction between tumor and immune system, and
iNOS is known as a surrogate marker of M1 macrophages activation. The goal of the study
was to investigate the role of iNOS polymorphisms as prognostic marker in mCRC patients.
Materials and methods
Functional significant polymorphisms in the promoter of INOS gene were analyzed by PCR-
based and direct DNA sequencing in 4 cohorts of patients receiving bevacizumab based
first-line chemotherapy: two evaluation cohorts (TRIBE ARM A and ARM B) and two valida-
tion cohorts (FIRE 3 arm A and MOMA). The relation of the SNPs with PFS and OS was
evaluated through Kaplan-Meier method and log-rank test. Subgroup analyses according to
RAS status were preplanned.
Results
In the exploratory cohort 1 (TRIBE A), patients with CCTTT any>13repeats (N = 57) showed
improved median PFS compared with patients carrying the13/13 repeats variant (N =
152) (HR, 0.64; 95%CI 0.44–0.92, p = 0.010). Similar results were shown adopting the
>26repeats/26 repeats (HR, 0.56; 95%CI 0.36–0.87, p = 0.005). In RAS mutant, patient
with any>13 repeats (N = 24) had improved PFS results compared with those carrying the
13/13 repeats variant (N = 81) (HR, 0.51; 95%CI 0.30–0.87, p = 30.009). Similar results
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were found adopting the >26 repeats/26 repeats cut off: (HR, 0.52; 95%CI 0.27–0.98, p =
0.035). These data were partially confirmed in the exploratory cohort 2 (TRIBE B): a better
median PFS was observed in patients with >26 repeats vs26 repeats (N = 205) patients.
However, these data were not confirmed in the two validation cohorts.
Conclusion
We failed to replicate the exploratory findings in both validation sets. The CCTTT polymor-
phic region of the INOS gene does not predict outcome in mCRC receiving bevacizumab
based first line chemotherapy. Further investigations are needed to reveal mechanisms
between tumor, immune system and chemotherapy response.
Introduction
Significant progresses have been made over the last years in the treatment of mCRC. Currently
first-line therapy of patients affected by mCRC is based on the use of a combination of cyto-
toxics with monoclonal antibodies either anti-VEFG (bevacizumab) or anti-EGFR (cetuximab,
panitumumab). Among cytotoxics, fluoropirimidine-based treatments represent the standard
of care as monotherapy, doublet combinations (FOLFOX, XELOX or FOLFIRI) or triplet
combination (FOLFOXIRI) [1–6].
In the last years, immunotherapy showed promising results in solid tumors especially in
lung cancer and in melanoma, demonstrating an overall survival (OS) and progression-free
survival (PFS) benefit in several trials [7, 8]. The role of immunotherapy in mCRC is currently
under investigation. The anti-PD1 antibodies pembrolizumab and nivolumab and the combi-
nation of nivolumab plus the anti-CTLA4 ipilimumab showed promising results in ongoing
clinical trials in a subgroup of patients with microsatellite instability in advanced lines of treat-
ment [9, 10]. Up today, many efforts are ongoing, firstly, in order to identify a role for immu-
notherapy in earlier lines of treatment and its possible applications in combination with
chemotherapy; secondly to unveil, biomarkers leading to identify a wider range of patients
possible benefitting from this strategy [11–14].
The interaction of tumor cells with stroma is closely connected with immune modulation
and represents an appealing research field. In this complex mechanism macrophages play a
crucial role in the balance of pro and anti tumorigenic stimuli. In particular, macrophages
derived from monocyte precursors undergo specific differentiation depending on the local tis-
sue environment [15].
The classically activated M1 macrophages are characterized by the production of high levels
of pro-inflammatory cytokines, high production of reactive nitrogen and oxygen intermedi-
ates, and the promotion of Th1 responses, through the upregulation of inducible nitric oxide
synthase (NOS2 or iNOS) resulting in tumoricidal effect [15–18].
INOS is a NADPH-dependent enzyme catalyzing the production of nitric oxide (NO) from
L-arginine [19] and is known as a surrogate marker of M1 macrophages activation [20, 21]. Its
relation with colorectal cancer has been investigated and high levels of NOS2 expression where
related to colorectal cancer progression and development and with poor prognosis [22]. A pos-
sible explanation for such phenomenon is based on the relationship between high macrophage
expression and increase of VEGF production and stimulation of angiogenesis and tumor
growth [23, 24]. Several polymorphisms have been identified in this gene and many studies
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identified a highly polymorphic pentanucleotide (CTTTT)n repeat, at position– 2.6 kb in the
promoter of iNOS [25] as possible a surrogate of NOS2 expression [26, 27].
Based on the above reported considerations, we hypothesized that iNOS polymorphisms
might allow clarifying mechanisms related to the interaction between immune system and
CRC.and might have a prognostic role in mCRC patients receiving bevacizumab- based first
line treatment in three large and modern phase II/III clinical trials.
Materials and methods
Patients’ population
This study investigated 4 independents cohorts of mCRC patients receiving bevacizumab
based first-line treatment:
1. an evaluation cohort of 227 patients receiving FOLFIRI plus bevacizumb enrolled in the
TRIBE trial (TRIBE ARM A—exploratory cohort 1),
2. an evaluation cohort of 231 patients receiving FOLFOXIRI plus bevacizumb enrolled in the
TRIBE trial (TRIBE ARM B—exploratory cohort 2),
3. a validation cohort of 301 patients receiving FOLFIRI plus bevacizumb enrolled in the
FIRE-3 trial (FIRE-3—validation cohort 1)
4. a validation cohort of 187 patients receiving FOLFOXIRI plus bevacizumb enrolled in the
MOMA trial (MOMA–validation cohort 2).
The above-mentioned studies were carried out between 2007 and 2015 in Italy, Germany
and Austria. Main inclusion criteria included: first occurrence of metastatic disease in patients
with histological diagnosis of adenocarcinoma of colon or rectum. Further details on inclusion
and exclusion criteria have previously been described [28–30].
In TRIBE ARM A FOLFIRI consisted of a 180 mg/m2 intravenous infusion of irinotecan fol-
lowed by a 200 mg/m2 intravenous infusion of leucovorin, a 400 mg/m2 intravenous bolus of
fluorouracil, and a 2400 mg/m2 continuous infusion of fluorouracil for 46 h. In TRIBE ARM B
and MOMA FOLFOXIRI consisted of a 165 mg/m2 intravenous infusion of irinotecan, fol-
lowed by an 85 mg/m2 intravenous infusion of oxaliplatin given concurrently with 200 mg/m2
leucovorin for 120 min, followed by a 3200 mg/m2 continuous infusion of fluorouracil for 48 h.
Treatment was administered every 2 weeks for up to 12 cycles followed by maintenance treat-
ment with fluorouracil, leucovorin until disease progression, intolerable toxicities, or patient
withdrawal. Tumour assessment by CT scan was done every 8 weeks until disease progression.
In FIRE-3 trial FOLFIRI consisted of irinotecan 180 mg/m2, leucovorin 200 mg/m2, 5-fluo-
rouracil 400 mg/m2 bolus infusion and 5-fluorouracil 2400 mg/m2 as a 48-hour continuous
infusion. Treatment was administered every 2 weeks until disease progression, intolerable tox-
icities, or patient withdrawal. Responses were measured by contrast-enhanced computed
tomography (CT) scans after 6 and 12 weeks of treatment, and every 10 weeks thereafter
according to RECIST v1.0.
This study was approved by The Health Sciences Review Board (HSIRB) -The Office for the
Protection of Research Subjects 3720 South Flower Street, Third Floor Los Angeles, CA
90089–0706. All patients signed an informed consent.
Genotyping analysis
NOS2 single-nucleotide polymorphisms (SNPs) were selected according to the following
criteria:
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• minor allele frequency>5% in Caucasians according to the ENSEMBL database (http://
www.ensembl.org/index.html)
• citation on PubMed and possible relation with cancer [26, 27, 31].
• functional or predicted functional relevance of gene transcription or protein expression.
Functional significance was predicted based on information provided by the National Insti-
tute of Environmental Health Science SNP Function Prediction, Queen’s University F-SNP,
and the location of the SNP in the protein-coding region of the gene (http://snpinfo.niehs.
nih.gov/snpinfo/snptag.htm).
Genomic DNA was extracted from peripheral whole blood in TRIBE and MOMA trials and
from formalin-fixed paraffin-embedded (FFPE) tissues in FIRE-3 using the QIAmp Kit (Qia-
gen, Valencia, CA, USA) according to the manufacturer’s protocol (www.qiagen.com).
PCR-based direct DNA sequence analysis using ABI 3100A Capillary Genetic Analyzer and
Sequencing Scanner v1.0 (Applied Biosystems, Waltham, MA, USA) was performed for geno-
typing the SNPs. The extracted DNA was amplified using the primer sets shown in Table 1,
and analyzed by PCR-based direct DNA sequencing. For quality control purposes, a random
selection of 10% of the samples were re-examined for each polymorphism, and the genotype
concordance rate was 100%. The investigator analyzed the sequencing data using the ABI
Sequencing Scanner v1.0 (Applied Biosystems, Life Technologies, Grand Island, NY, USA)
and was blinded to the clinical data set.
For the primary end point analysis, NOS2 CCTTT repeats cut-offs were defined based on
the maximum chi-square method for PFS and categorized as13/13 repeats for patients
with13 repeat in each allele and any >13 repeats for patients with at least on allele with>13
repeats.
Exploratory analyses were conducted adopting the sum of repeats in each allele and the pre-
defined cut off was26 repeat/ >26 repeats.
Hardy-Weinberg Equilibrium was assessed by means of Chi-square test.
Statistical analysis
The primary aim of the study was the identification of a prognostic/predictive role for the
selected SNPs (NOS2 rs27779248 and CCTTT repeat) in mCRC patients treated with first-line
chemotherapy with bevacizumab. Primary endpoint was PFS. The secondary endpoints were
OS and tumor response. Table 1 shows SNPs characteristics and adopted primers.
The distribution of patient baseline clinicopathologic characteristics were compared using
the Chi-square test between the four cohorts.
The impact of NOS2 SNPS in relation with FOLFIRI plus bevacizumab treatment was eval-
uated in TRIBE arm A and in FIRE-3 as exploratory and validation cohorts respectively.
The impact of NOS2 SNPS in relation with the addiction of oxaliplatin was evaluated in
TRIBE arm B and in MOMA as exploratory and validation cohorts respectively.
The relation of the NOS2 SNPs with PFS and OS was evaluated through Kaplan-Meier
method and log-rank test in the overall population.
Table 1. Investigated SNP characteristics.
rs number Location Forward primer Reverse Primer Minor Allele Frequency Recessive Allele
CCTTTrepeat NA promoter region ACCCCTGGAAGCCTACAACTGCAT GCCACTGCACCCTAGCCTGTCTCA NA NA
277AG rs2779248 promoter region CTTCACCCAACCCACCTCTT AGCTCCCTGCTGAGGAAAA 0.33 G
https://doi.org/10.1371/journal.pone.0193640.t001
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OS was defined as the time from randomization to death due to any cause, PFS was defined
as the time from randomization to first documented disease progression or death due to any
cause. Patients were censored at the time of last follow-up if no event observed. Patients were
defined as responders when achieving complete or partial response and non-responders when
stable or progressive disease occurred as defined by RECIST 1.0 criteria. The relation of the
NOS2 SNPs with PFS and OS was evaluated through Kaplan-Meier method and log-rank test
in the overall population.
Multivariable Cox regression model was used to assess the independent effect of two SNPs
on PFS and OS when adjusting for the baseline demographic, clinical, and tumor characteris-
tics that were associated with outcomes. Correlation of SNPs with response was estimated by
the multivariable logistic regression, adjusting for the same baseline characteristics. Subgroup
analyses according to RAS status were preplanned.
With 209 patients (163 PFS events) in the exploratory cohort 1, we would have 80% power
to detect a minimum hazard ratio (HR) of 0.59 to 0.65 on PFS for a SNP with a minor allele
frequency from 0.1 to 0.5 using a two-sided 0.05 level log-rank test. When applied the same
model and test, we would have at least 81%, 89%, and 74% power to detect the same HR in the
exploratory cohort 2 (225 patients, 161 PFS events), validation cohort 1 (280 patients, 239 PFS
events), and validation cohort 2 (178 patients, 125 PFS events), respectively.
All statistical analyses were performed by SAS 9.4 (SAS Institute, Cary, NC, USA). All tests
were two sided at a significant level of 0.05.
Results
Baseline clinicopathologic characteristics in the four cohorts are summarized in Table 2. Dif-
ferences in terms of age, primary tumor site, primary tumor resection, performance status,
KRAS and RAS status were identified across patients enrolled in the trials (Table 2).
TRIBE ARM A—Exploratory cohort 1
Associations of clinicopathologic characteristics of exploratory cohort 1 with outcome are pre-
sented in S1 Table. Median follow up was 50.6 months; median PFS and OS were respectively
9.5 months and 25.8 months. Resection of the primary tumors, ECOG performance status,
and BRAF status were significantly associated with PFS and OS. Furthermore age, primary
tumor site, time to metastases, and previous adjuvant chemotherapy significantly correlated
with OS (S1 Table).
Genotyping results. Associations between NOS2 SNPs and outcomes in exploratory
cohort 1 are summarized in Table 3.
In the overall population, patients with CCTTT any > 13 repeats (N = 57) showed improved
median PFS compared with patients carrying the13/13 repeats variants (N = 152), respec-
tively 11.1 and 9.5 months (HR, 0.64; 95% CI 0.44–0.92, p = 0.010). This association remained
significant in multivariable analysis (HR, 0.62, 95%, CI 0.41–0.93, p = 0.021) (Fig 1).
Exploratory analyses adopting the> 26 repeats (N = 34) and 26 repeats (N = 175) cut off
showed similar results with a median PFS of 11.1 and 9.5 months respectively (HR, 0.56; 95%
CI 0.36–0.87, p = 0.005). This association remained significant in multivariable analysis (HR,
0.61, 95%, CI 0.38–0.99, p = 0.047). No associations were identified with NOS2 rs27779248
SNP.
Subgroup analyses: In RAS mutant patients those carrying any > 13 repeats (N = 24)
showed better median PFS compared with those with13/13 repeats (N = 81), 11.6 and 9.0
months respectively (HR, 0.51; 95% CI 0.30–0.87, p = 0.009). This association remained signif-
icant in multivariable analysis (HR, 0.40, 95%, CI 0.22–0.74, p = 0.003). Similar results were
NOS2 polymorphisms in metastatic colorectal cancer patients
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observed adopting the> 26 repeats (N = 15) and 26 repeats (N = 90) cut off (median PFS
11.1 and 9.2 months HR for univariate, 0.52; 95% CI 0.27–0.98, p = 0.035; HR for multivariate
HR, 0.54, 95%, CI 0.27–1.06, p = 0.073). (Table 4).
TRIBE ARM B—Exploratory cohort 2
Patients characteristics and association with outcome for exploratory cohort 2 are presented in
S2 Table. The median follow up was 46.4 months; median PFS and OS were 11.7 and 30.3
Table 2. Clinicopathological features of patients.
Characteristics N TRIBE arm A
Exploratory cohort 1
N = 209
TRIBE arm B
Exploratory cohort 2
N = 225
FIRE-3
Validation cohort 1
N = 280
MOMA
Validation cohort 2
N = 178
P Value
Sex 0.27
Males 553 128 (61%) 136 (60%) 186 (66%) 103 (58%)
Females 339 81 (39%) 89 (40%) 94 (34%) 75 (42%)
Age <0.001
 65 576 151 (72%) 152 (68%) 145 (52%) 128 (72%)
> 65 316 58 (28%) 73 (32%) 135 (48%) 50 (28%)
Primary tumor site 0.041
Right side 263 53 (25%) 76 (34%) 71 (25%) 63 (35%)
Left side 598 143 (68%) 138 (61%) 202 (72%) 115 (65%)
Number of metastases 0.50
1 287 89 (43%) 95 (42%) 103 (37%) NA
2 255 83 (40%) 91 (40%) 81 (29%) NA
3 129 37 (18%) 39 (17%) 53 (19%) NA
Liver limited disease 0.72
Yes 285 63 (30%) 77 (34%) 92 (33%) 53 (30%)
No 607 146 (70%) 148 (66%) 188 (67%) 125 (70%)
Synchronous disease 0.22
Yes 528 172 (82%) 177 (79%) 179 (64%) NA
No 143 37 (18%) 48 (21%) 58 (21%) NA
Primary tumor resection <0.001
Yes 570 131 (63%) 153 (68%) 245 (88%) 41 (23%)
No 322 78 (37%) 72 (32%) 35 (13%) 137 (77%)
Adjuvant chemotherapy 0.13
Yes 106 26 (12%) 29 (13%) 51 (18%) NA
No 608 183 (88%) 196 (87%) 229 (82%) NA
Performance status <0.001
ECOG 0 677 170 (81%) 200 (89%) 153 (55%) 154 (87%)
ECOG 1 214 38 (18%) 25 (11%) 127 (45%) 24 (13%)
KRAS status <0.001
Wildtype 412 88 (42%) 87 (39%) 237 (85%) NA
Mutant 225 83 (40%) 99 (44%) 43 (15%) NA
RAS status <0.001
Wildtype 345 50 (24%) 59 (26%) 191 (68%) 45 (25%)
Mutant 412 105 (50%) 112 (50%) 77 (28%) 118 (66%)
BRAF status 0.53
Wildtype 727 160 (77%) 173 (77%) 248 (89%) 146 (82%)
Mutant 64 11 (5%) 13 (6%) 23 (8%) 17 (10%)
https://doi.org/10.1371/journal.pone.0193640.t002
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Table 3. Associations between CCTTT repeats and outcomes.
Tumor response Progression-free survival Overall survival
SNP N Yes No Median (95%CI),
months
Univariate HR (95%
CI)
Multivariable HR (95%
CI)
Median (95%CI),
months
Univariate HR (95%
CI)
Multivariable HR
(95%CI)
Exploratory cohort 1—TRIBE arm A (FOLFIRI plus bev)
NOS2 rs2779248
A/A 77 44(59%) 30(41%) 10.3(8.4,11.0) 1(reference) 1(reference) 26.1(21.1,33.6) 1(reference) 1(reference)
A/G 106 63(61%) 41(39%) 9.7(9.2,11.1) 1.18(0.84,1.66) 1.12(0.79,1.61) 26.0(20.8,30.9) 1.07(0.77,1.50) 0.96(0.68,1.37)
G/G 41 19(49%) 20(51%) 9.5(7.9,13.6) 0.78(0.50,1.20) 0.77(0.48,1.22) 26.1(18.4,37.8) 1.11(0.72,1.69) 1.31(0.84,2.03)
P value 0.31 0.10 0.26 0.87 0.35
A/G or G/G 147 82(57%) 61(43%) 9.7(9.3,11.1) 1.03(0.75,1.42) 1.00(0.72,1.39) 26.1(20.8,30.8) 1.08(0.79,1.48) 1.05(0.76,1.46)
P value 0.87 0.85 0.99 0.62 0.76
A/A or A/G 183 107(60%) 71(40%) 9.7(9.0,10.8) 1(reference) 1(reference) 26.1(22.5,30.8) 1(reference) 1(reference)
G/G 41 19(49%) 20(51%) 9.5(7.9,13.6) 0.71(0.48,1.05) 0.72(0.47,1.10) 26.1(18.4,37.8) 1.06(0.73,1.55) 1.34(0.90,1.99)
P value 0.14 0.064 0.13 0.75 0.15
NOS2 CCTTT
13/13 152 81(54%) 69(46%) 9.5(8.6,10.5) 1(reference) 1(reference) 24.9(20.5,27.9) 1(reference) 1(reference)
Any >13 57 37(71%) 15(29%) 11.1(8.8,12.7) 0.64(0.44,0.92) 0.62(0.41,0.93) 30.3(20.5,42.7) 0.75(0.53,1.07) 0.80(0.54,1.19)
P value 0.049 0.010 0.021 0.10 0.28
26† 175 97(56%) 76(44%) 9.5(8.6,10.5) 1(reference) 1(reference) 25.0(20.5,27.9) 1(reference) 1(reference)
>26† 34 21(72%) 8(28%) 11.1(8.8,16.6) 0.56(0.36,0.87) 0.61(0.38,0.99) 36.1(20.5,49.1) 0.70(0.45,1.07) 0.73(0.45,1.18)
P value 0.20 0.005 0.047 0.097 0.20
Exploratory cohort 2—TRIBE arm B (FOLFOXIRI plus bev)
13/13 172 111(67%) 55(33%) 11.7(10.1,13.0) 1(reference) 1(reference) 28.5(23.4,34.3) 1(reference) 1(reference)
Any >13 53 35(69%) 16(31%) 12.8(9.3,17.2) 0.94(0.66,1.35) 1.11(0.76,1.64) 33.4(20.6,42.0) 0.83(0.56,1.21) 0.93(0.62,1.39)
P value 0.86 0.74 0.59 0.33 0.72
26† 205 130(66%) 67(34%) 11.3(10.1,12.5) 1(reference) 1(reference) 28.2(23.4,33.4) 1(reference) 1(reference)
>26† 20 16(80%) 4(20%) 15.6(11.1,28.8) 0.57(0.32,1.00) 0.66(0.37,1.19) 42.0(30.9,66.1) 0.50(0.26,0.95) 0.58(0.30,1.11)
P value 0.33 0.045 0.17 0.031 0.10
Validation cohort 1—FIRE-3 (FOLFIRI plus bev)
13/13 229 129(61%) 83(39%) 10.0(9.2,10.9) 1(reference) 1(reference) 23.7(21.3,26.5) 1(reference) 1(reference)
Any >13 51 29(60%) 19(40%) 13.2(9.8,14.9) 0.79(0.56,1.11) 0.77(0.54,1.09) 28.8(20.1,42.9) 0.75(0.51,1.11) 0.79(0.53,1.18)
P value 0.59 0.16 0.14 0.15 0.25
26† 253 143(61%) 91(39%) 10.1(9.3,11.3) 1(reference) 1(reference) 23.7(21.5,26.7) 1(reference) 1(reference)
>26† 27 15(58%) 11(42%) 12.0(9.8,15.1) 0.79(0.52,1.21) 0.81(0.52,1.27) 31.5(18.9,43.7) 0.69(0.43,1.13) 0.74(0.44,1.24)
P value 0.51 0.27 0.36 0.14 0.25
Validation cohort 2—MOMA (FOLFOXIRI plus bev)
13/13 132 83(64%) 47(36%) 9.1(7.9,9.9) 1(reference) 1(reference) 24.7(19.4,30.8) 1(reference) 1(reference)
Any >13 46 28(67%) 14(33%) 10.3(7.9,10.6) 0.99(0.67,1.47) 0.84(0.56,1.27) 27.3(16.9,43.3) 0.83(0.51,1.36) 0.86(0.52,1.43)
P value 0.62 0.97 0.41 0.46 0.57
26† 157 99(66%) 52(34%) 9.1(8.2,9.9) 1(reference) 1(reference) 24.7(19.4,30.8) 1(reference) 1(reference)
>26† 21 12(57%) 9(43%) 10.5(7.7,12.6) 0.87(0.51,1.50) 0.86(0.49,1.50) 27.3(16.9,41.2) 0.86(0.46,1.62) 1.00(0.53,1.92)
P value 0.43 0.62 0.59 0.64 0.99
 P value was based on the multivariable logistic regression for tumor response, log-rank test for PFS and OS on the univariate analysis and Wald test in the
multivariable Cox regression model. Multivariable models were adjusted for sex, age, performance status, primary tumor site, primary tumor resection, adjuvant
chemotherapy, number of metastases, high ALP, RAS and BRAF status in the exploratory cohorts 1 and 2; adjusted for sex, age, performance status, primary tumor site,
primary tumor resection, adjuvant chemotherapy, liver limited disease, RAS status and BRAF status in the validation cohort 1; adjusted for age, performance status and
liver limited disease in the validation cohort 2.
† Sum of (CA) repeats of two alleles.
https://doi.org/10.1371/journal.pone.0193640.t003
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months, respectively. Time to metastases and resection of the primary tumors were signifi-
cantly associated with PFS and OS. Primary tumor site, number of metastases, ECOG perfor-
mance status, BRAF status were also significantly associated with OS (S2 Table).
Genotyping results. Associations between CCTTT repeats and outcomes in exploratory
cohort 2 are summarized in Table 3.
No association with outcome was identified adopting the any > 13 (N = 53) vs13/13
repeats (N = 172) cut off (HR for PFS in univariate, 0.94; 95% CI 0.66–1.35, p = 0.74) (Fig 2).
Median PFS for patients with> 26 repeats (N = 20) compared to 26 repeats (N = 205)
was 15.6 versus 11.5 months, respectively (HR, 0.57; 95% CI 0.32–1.00, p = 0.045). This associ-
ation remained significant in multivariable analysis (HR, 0.66, 95%, CI 0.37–1.19, p = 0.017).
Moreover, patients with > 26 repeats had a better median OS compared with those
carrying 26 repeats, 42.0 and 28.2 months respectively (HR, 0.50; 95% CI 0.26–0.95,
p = 0.031), however such association was lost in multivariate analyses (HR, 0.58; 95% CI 0.30–
1.11, p = 0.10).
Subgroup analyses: among RAS mutant patients no significant outcome differences in PFS
were observed when adopting the any > 13 vs13/13 repeats cut off (HR for univariate,
Fig 1. Exploratory cohort 1 (tribe—A). PFS results in any > 13 repeats vs13/13 repeats.
https://doi.org/10.1371/journal.pone.0193640.g001
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0.86; 95% CI 0.49–1.52, p = 0.61; HR for multivariate 1.12; 95% CI 0.60–2.09 p = 0.73). Patients
with>26 repeats (N = 7) had a median PFS of 28.8 months compared to 11.4 months in
patients with 26 repeats (N = 105), such difference was not statistically significant (HR in
univariate, 0.38; 95% CI 0.12–1.21, p = 0.087; HR in multivariate 0.41; 95% CI 0.12–1.38,
p = 0.15) (Table 4).
FIRE -3—Validation cohort 1
Clinicopathologic characteristics and associations with outcome for validation cohort 1 are
presented in S3 Table. The median follow up was 40.8 months; median PFS and OS were 10.3
and 24.7 months, respectively. Primary tumor site, ECOG performance status, and BRAF sta-
tus were significantly associated with PFS and OS. Additionally, number of metastatic sites,
Table 4. Associations between CCTTT repeats and outcomes in RAS mutant patients.
Tumor response Progression-free survival Overall survival
SNP N Yes No Median (95%CI),
months
Univariate HR
(95%CI)
Multivariable HR
(95%CI)
Median (95%CI),
months
Univariate HR
(95%CI)
Multivariable HR
(95%CI)
Exploratory cohort 1— TRIBE arm A (FOLFIRI plus bev)
13/13 81 44(55%) 36(45%) 9.0(7.8,9.9) 1(reference) 1(reference) 22.7(19.1,27.9) 1(reference) 1(reference)
Any >13 24 15(68%) 7(32%) 11.6(8.8,14.9) 0.51(0.30,0.87) 0.40(0.22,0.74) 29.6(18.8,43.6) 0.86(0.51,1.44) 0.75(0.43,1.33)
P value 0.27 0.009 0.003 0.56 0.33
26† 90 49(55%) 40(45%) 9.2(7.8,10.3) 1(reference) 1(reference) 23.3(19.5,28.6) 1(reference) 1(reference)
>26† 15 10(77%) 3(23%) 11.1(8.7,23.6) 0.52(0.27,0.98) 0.54(0.27,1.06) 26.1(17.8,55.0) 0.73(0.38,1.42) 0.80(0.40,1.60)
P value 0.21 0.035 0.073 0.35 0.53
Exploratory cohort 2—TRIBE arm B (FOLFOXIRI plus bev)
13/13 89 58(67%) 29(33%) 11.0(9.7,12.5) 1(reference) 1(reference) 26.2(20.4,31.0) 1(reference) 1(reference)
Any >13 23 15(68%) 7(32%) 13.4(9.0,23.1) 0.86(0.49,1.52) 1.12(0.60,2.09) 31.3(18.5,34.3) 0.98(0.58,1.66) 1.27(0.71,2.28)
P value 0.80 0.61 0.73 0.95 0.43
26† 105 68(67%) 34(33%) 11.4(9.9,12.4) 1(reference) 1(reference) 25.8(20.4,30.8) 1(reference) 1(reference)
>26† 7 5(71%) 2(29%) 28.8(6.4,33.6) 0.38(0.12,1.21) 0.41(0.12,1.38) 40.0(30.9,56.3) 0.60(0.24,1.49) 0.64(0.24,1.70)
P value 0.83 0.087 0.15 0.27 0.37
Validation cohort 1—FIRE-3 (FOLFIRI plus bev)
13/13 63 33(55%) 27(45%) 10.1(8.3,12.7) 1(reference) 1(reference) 20.6(16.7,26.5) 1(reference) 1(reference)
Any >13 14 6(46%) 7(54%) 11.2(8.7,15.1) 0.93(0.48,1.78) 0.91(0.45,1.83) 28.4(11.2,42.9) 0.77(0.37,1.57) 0.76(0.35,1.63)
P value 0.74 0.82 0.78 0.45 0.48
26† 68 35(54%) 30(46%) 10.1(8.5,12.5) 1(reference) 1(reference) 20.6(16.7,25.1) 1(reference) 1(reference)
>26† 9 4(50%) 4(50%) 14.4(1.9,17.6) 0.77(0.37,1.63) 0.69(0.31,1.53) 31.5(7.0,45.8) 0.59(0.25,1.39) 0.54(0.22,1.34)
P value 0.88 0.49 0.36 0.21 0.19
Validation cohort 2—MOMA (FOLFOXIRI plus bev)
13/13 90 61(69%) 27(31%) 9.0(7.9,10.3) 1(reference) 1(reference) 25.4(19.4,32.6) 1(reference) 1(reference)
Any >13 28 17(68%) 8(32%) 10.3(7.0,10.6) 1.23(0.74,2.03) 1.01(0.59,1.73) 27.3(16.2,40.9+) 0.91(0.50,1.66) 0.98(0.52,1.82)
P value 0.94 0.41 0.96 0.76 0.94
26† 107 73(72%) 29(28%) 9.0(8.2,10.3) 1(reference) 1(reference) 24.7(18.9,32.6) 1(reference) 1(reference)
>26† 11 5(45%) 6(55%) 10.5(4.2,17.5) 0.89(0.41,1.93) 0.84(0.38,1.88) 27.9(10.3,37.2+) 0.77(0.33,1.80) 0.89(0.37,2.13)
P value 0.074 0.76 0.67 0.54 0.80
 P value was based on the multivariable logistic regression for tumor response, log-rank test for PFS and OS on the univariate analysis and Wald test in the
multivariable Cox regression model. Multivariable models were adjusted for sex, age, performance status, primary tumor site, primary tumor resection, adjuvant
chemotherapy, number of metastases, high ALP, RAS and BRAF status in the exploratory cohorts 1 and 2; adjusted for sex, age, performance status, primary tumor site,
primary tumor resection, adjuvant chemotherapy, liver limited disease, RAS status and BRAF status in the validation cohort 1; adjusted for age, performance status and
liver limited disease in the validation cohort 2.
† Sum of (CA) repeats of two alleles.
https://doi.org/10.1371/journal.pone.0193640.t004
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liver limited disease, and time to metastasis were also significantly associated with OS (S3
Table).
Genotyping results. Associations between CCTTT repeats and outcomes in validation
cohort 1 are summarized in Table 3.
No associations were identified in terms of outcome adopting the any > 13 (N = 51) vs
13/13 repeats (N = 229) cut off (PFS: HR for univariate, 0.79; 95% CI 0.56–1.11, p = 0.16;
HR for multivariate 0.77; 95% CI 0.54–1.09 p = 0.14), nor the>26 (N = 27) vs 26 repeats
(N = 253) cut off (PFS: HR for univariate, 0.79; 95% CI 0.52–1.21, p = 0.27; HR for multivariate
0.81; 95% CI 0.52–1.27 p = 0.36). No statistically significant outcome differences were observed
among RAS mutant patients (N = 77) (Table 4) (Fig 3).
MOMA—Validation cohort 2
Associations between clinical features and outcomes in validation cohort 2 are summarized in
S4 Table.
Fig 2. Exploratory cohort 2 (tribe—B). PFS results in any > 13 repeats vs13/13 repeats.
https://doi.org/10.1371/journal.pone.0193640.g002
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The median follow up was 25.3 months, median PFS and OS were respectively 9.2 and 25.3
months. Resection of the primary tumors and ECOG performance status were significantly
associated with PFS and OS; liver limited disease was also associated with OS (S4 Table).
Genotyping results. Associations between CCTTT repeats and outcomes in exploratory
cohort 2 are summarized in Table 3.
No associations were identified in terms of outcome adopting the any > 13 (N = 46) vs
13/13 repeats (N = 132) cut off (HR for univariate, 0.99; 95%, CI 0.67–1.47, p = 0.97; HR
for multivariate, 0.84; 95%, CI 0.56–1.27, p = 0.41) nor the>26 (N = 21) vs 26 repeats
(N = 157) cut off (HR for univariate, 0.87; 95%, CI 0.51–1.50, p = 0.62; HR for multivariate,
0.86; 95%, CI 0.49–1.50, p = 0.59). No statistically significant outcome differences were
observed among RAS mutant patients (N = 118) (Table 4) (Fig 4).
Discussion
The identification of prognostic markers in mCRC patients, and in particular in the first-line
treatment setting represents a crucial issue in modern clinical oncology. Prognostic factors
help identifying patient subgroups with peculiar tumor phenotypes requiring personalized
Fig 3. Validation cohort 1 (FIRE-3). PFS results in any > 13 repeats vs13/13 repeats.
https://doi.org/10.1371/journal.pone.0193640.g003
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treatment strategies. Thanks to the recent progresses and emerging data on immunotherapeu-
tic treatment strategies for mCRC, the interaction of immune system with colorectal cancer is
becoming an appealing research field and immune-related markers are emerging as possible
new prognostic or predictive factors in this setting.
For the first time a polymorphic region in the promoter of NOS2 gene has been analyzed as
surrogate marker of M1 macrophages activity and possible prognostic marker in patients
receiving a first-line treatment with bevacizumab enrolled in modern, randomized phase III
and II clinical trials [32–34]. We specifically selected patients receiving anti-angiogenetic
drugs in modern clinical trials due to the strong association of macrophage activity and angio-
genesis regulation.
The exploratory cohorts involved patients treated in the phase III TRIBE trial receiving first
line treatment with FOLFIRI + bevacizumab (exploratory cohort 1) or FOLFOXIRI + bevaci-
zumab ((exploratory cohort 2). Based on the already observed correlation of high number of
NOS2 repeats with increased NOS2 expression, we hypothesized a better outcome in patients
Fig 4. Validation cohort 2 (MOMA). PFS results in any > 13 repeats vs13/13 repeats.
https://doi.org/10.1371/journal.pone.0193640.g004
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with higher number of NOS2 repeats. The role of NOS2 repeats was firstly identified in the
cohort 1 but only partially confirmed in the cohort 2.
To challenge our data, we identified two validation cohorts: one treated with FOLFIRI +
bevacizumab in the FIRE-3 study and the other treated with FOLFOXIRI + bevacizumab in
the MOMA study. No significant clinical differences were observed among the additional 2
cohorts of patients, thus we failed to replicate the exploratory results in both validation sets.
Based on the power analyses calculation, no major concerns on sample size can be raised.
In the present study we moved from a strong biological rationale [35, 36] and we selected a
relatively innovative marker, since only a few studies focused on NOS2 polymorphisms and
their connection with M1 macrophage tumoral infarction [37]. Moreover nitric oxide is tightly
involved in angiogenesis regulation and tumor growth [38].
As additional strengthen points we have to consider that more than 900 patients were
included in the present study; study population presented comparable clinical features and
was enrolled in practice changing clinical trials of first line chemotherapy for mCRC. The
adoption of a rigorous study design with 2 validation cohorts increases the relevance of our
findings.
As limitation points, we have to mention the lack of confirmatory preclinical data obtained
from our samples, supporting the correlation between number of CCTTT repeats and iNOS
expression. Unfortunately, adequate tumoral tissue was not available to solve this issue.
As possible explanation of our negative result, we have to consider that a single SNP might
not catch the complexity of interactions between tumor cells and microenvironment that are
regulated both by immune related factors and angiogenesis related mediators. Moreover we
have to acknowledge that other sources of NO production might increase the complexity of
the scenario.
In particular NO is produced not only by NOS2 but also by the endothelial NOS which plays
a central role in maintaining endothelial cell functional integrity. [19]. Previous studies corre-
lated VEGF inhibition mediated by bevacizumab with a decrease in eNOS expression and thus
in NO production [21].
However, despite the negative results, our findings underline the importance of investigat-
ing mechanisms regulating the interactions of tumor development, chemotherapy response
and immune system in order to identify new immunotherapeutic strategies effective in
patients receiving chemotherapy.
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